# Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

> **NCT05418556** · PHASE4 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 3944 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT05418556
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-21
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 3944 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418556, "Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05418556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*